RAB18

Across TCGA pan-cancer cohorts, RAB18 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAB18 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAB18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB18 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where RAB18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.193	0.849	.003	43	view →
HNSC	OS	Median	IV	0.937	0.605	.002	37	view →
CCRCC	DFS	Median	III,IV	0.982	0.747	.011	15	view →
PDAC	OS	Median	IV	0.381	0.951	.006	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAB18–LUAD (DFS)

Open the LUAD breakdown →